Home Biosimilar Antibodies Immunology & Inflammation Interleukins null Risankizumab (anti-IL-23) For research use only.
Not for use in humans.

Risankizumab (anti-IL-23)

Risankizumab targets the p19 subunit of IL-23. Risankizumab is indicated for the treatment of psoriasis and is safe and effective in maintaining remission in active Crohn's disease.

Risankizumab (anti-IL-23)

Click to purchase the isotype control of Risankizumab (anti-IL-23)

Selleck's Risankizumab (anti-IL-23) has been cited by 0 publication

1 Customer Review

Purity & Quality Control

Batch: Purity: 99% Protein concentration: 15.71mg/ml Endotoxin Level: ＜1EU/mg
99

Choose Selective Interleukins Inhibitors

Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description Risankizumab targets the p19 subunit of IL-23. Risankizumab is indicated for the treatment of psoriasis and is safe and effective in maintaining remission in active Crohn's disease.

Product Details

CAS No. 1612838-76-2
Molecular Weight 150 kDa
Isotype human IGg1, κ
Application Risankizumab (anti-IL-23)
Source CHO
Purification Protein G
Sterility 0.2 μM filtered
Formulation PBS Buffer, PH 7.4
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Risankizumab (anti-IL-23) | Risankizumab (anti-IL-23) supplier | purchase Risankizumab (anti-IL-23) | Risankizumab (anti-IL-23) cost | Risankizumab (anti-IL-23) manufacturer | order Risankizumab (anti-IL-23) | Risankizumab (anti-IL-23) distributor